The new facility is an addition to the company’s existing 50,000 sq. ft facility called Trent Gateway.
The new 7,000 sq. ft facility has been designed to specifically align with the revised EU GMP Annex-1 regulations – which outlines guidance on manufacturing sterile medicinal products covering topics such as wearing face masks and ensuring staff are qualified in this form of manufacturing.
Focus on Small Volume Liquids and Powders
The facility will focus on manufacturing aseptic and terminally sterilised small volume liquids and powders for parenteral, nasal, and pulmonary delivery.
Upperton Pharma Solutions claims its facility can support the development, clinical manufacturing and testing of batch sizes of up to 2,000 vials, pre-filled syringes, and pre-filled cartridges for liquid formulations and pre-sterilised powders.
New features to this facility include two cleanrooms with VHP isolation technology.
Commitment to Sterile Facility Builds
Nikki Whitfield, CEO, said, “We are delighted to complete the build of our sterile facility. The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.”
